奈妥吡坦止吐效果怎么样?

Netupitant has a significant antiemetic effect and can effectively prevent nausea and vomiting during the acute and delayed phases of cancer chemotherapy (within 25-120 hours after starting chemotherapy). Netupitant is a selective neurokinin 1 (NK1) receptor antagonist with potential antiemetic activity. In clinical trials, (fos)netupitant/palonosetron plus dexamethasone was associated with high rates of complete response (no emesis and no rescue medication) in the acute, delayed, and overall phases in patients receiving highly or moderately emetogenic chemotherapy, with efficacy maintained across multiple cycles.

Netupitant antiemetic trial

NEPA is a fixed oral combination of a novel NK1 receptor antagonist (RA), netopitant (NETU 300 mg), and palonosetron (PALO 0.50 mg), a pharmacologically distinct 5-HT3 RA. Better prevention of chemotherapy-induced nausea and vomiting (CINV) than oral palonosetron during a single chemotherapy cycle; the aim of this study was to maintain the efficacy/safety of netopitant during consecutive chemotherapy cycles.

research methods

This study was a multinational, double-blind study comparing the efficacy of a single dose of oral NEPA versus oral PALO, which was administered concomitantly with oral dexamethasone 12 mg (NEPA) or 20 mg (PALO) on day 1 of chemotherapy in chemotherapy-new patients receiving anthracycline/cyclophosphamide chemotherapy. The primary efficacy endpoint was delayed (25-120 h) complete response (CR: no vomiting, no rescue medication) in the first cycle. During the multi-cycle extension period, sustained efficacy was assessed by calculating the proportion of patients with overall (0-120 h) CR in cycles 2-4 and assessing the probability of sustained CR across multiple cycles.

Test results

Among 1455 randomly selected patients, 1286 (88%) participated in multi-cycle extended therapy, totaling 5969 cycles; 76% of patients completed ≥4 cycles of therapy. In cycles 1-4, the proportion of overall CR patients was significantly higher with NEPA than with oral PALO (74.3% vs 66.6%, 80.3% vs 66.7%, 83.8% vs 70.3%, and 83.8% vs 74.6%, respectively; P ≤ 0.001 per cycle). The cumulative percentage of sustained CR was also higher in NEPA patients across all 4 cycles (p<0.0001). NEPA was well tolerated across cycles.

Test conclusion

NEPA is a convenient, guideline-compliant fixed antiemetic combination that is effective and safe across multiple chemotherapy cycles.

Netupitant price

Netupitant was approved for marketing in China in August 2019. Due to different regional environments and conditions, the drug will also be different. Patients in need can consult the local hospital pharmacy for specific prices.

Through domestic professional overseas medical service organizations (such as Medical Companion Travel), we learned that the price of 1 capsule of 300mcg/0.5mcg is about $1,755 per box, but the price is not fixed due to various factors.

If necessary, you can obtain it through the help of domestic professional overseas medical service organizations (such as Medical Companion Travel). The medicine can be mailed to your home. It is guaranteed to be genuine and cost-effective. It is recommended to consult the customer service staff for specific costs and procedures. Obtaining medicine is guaranteed.

Recommended related articles:

References

Aapro M, Karthaus M, Schwartzberg L, Bondarenko I, Sarosiek T, Oprean C, Cardona-Huerta S, Hansen V, Rossi G, Rizzi G, Borroni ME, Rugo H. NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron. Support Care Cancer. 2017 Apr;25(4):1127-1135. doi: 10.1007/s00520-016-3502-x. Epub 2016 Nov 24. PMID: 27885469; PMCID: PMC5321708.